Leerink analyst Dan Leonard is "increasingly" cautious on Cepheid's (CPHD) opportunity in hospital acquired infection, as the value of molecular hospital acquired infection testing is under increased scrutiny. The analyst noted that syndromic panels that test a range of bugs associated with similar symptoms simultaneously may become more important, and could present a headwind for Cepheid, as healthcare providers might opt for panel testing in lieu of targeted testing. Clinical lab directors have also expressed a preference for more automation and broader test menus from the molecular diagnostics vendors, which can favor Hologic (HOLX), the analyst tells investors in a research note. Leonard has a Market Perform rating on Cepheid's shares and an Outperform rating on Hologic's shares.